Showing results (171-180 of 205) with videos related to

Sort By:
Pageof 21
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
Chinese Journal of Cancer|January 16, 2016
Expert consensus on maintenance treatment for metastatic colorectal cancer in ChinaRui-Hua Xu, Lin Shen, Jin Li, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2021
A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX)Yuan Cheng, Shu-Kui Qin, Jin Li, et al.
Lancet (London, England)|June 1, 2026
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 studyLin Shen, Xiaotian Zhang, Ke Ji, et al.
Cancer Research and Treatment|June 24, 2026
A Multinational, Retrospective, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Beyond First-line in East Asia (HER2+ GASTA Study)Do-Youn Oh, Winnie Yeo, Jen-Shi Chen, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Chinese Journal of Cancer|December 24, 2017
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialRui-Hua Xu, Lin Shen, Ke-Ming Wang, et al.
Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.
Pageof 21